FENC Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2016βFY2025
Fennec Pharmaceuticals Inc. had $44.6M of revenue in fiscal 2025, down 6.1% on the year before. Over five years, revenue changed +194.9% a year on average.
Last close Β· Oct 23, 2026
$10.08
2.3%Hi! I read Fennec Pharmaceuticals Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β6.1%
No. Sales fell 6.1% last year.
Does it make a profit?
β21.8%
No. It lost money last year.
How healthy are the accounts?
0 / 7
Weak. It passes 0 of 7 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Fennec Pharmaceuticals Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 12, 2026
Thursday Β· in 17 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 13, 2026 | Q2 '26 | After the market closes | 10-Q β |
| May 14, 2026 | Q1 '26 | After the market closes | 10-Q β |
| Mar 24, 2026 | Q4 '25 | After the market closes | 8-K β |
| Nov 13, 2025 | Q3 '25 | After the market closes | 10-Q β |
| Aug 14, 2025 | Q2 '25 | After the market closes | 10-Q β |
| May 14, 2025 | Q1 '25 | After the market closes | 10-Q β |
| Mar 10, 2025 | Q4 '24 | After the market closes | 8-K β |
| Nov 8, 2024 | Q3 '24 | After the market closes | 10-Q β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Fennec Pharmaceuticals Inc. had $44.6M of revenue in fiscal 2025, down 6.1% on the year before. Over five years, revenue changed +194.9% a year on average. Its operating margin was β14.1%, down 19.5Β pts: of every 100 in sales, about β14 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Fennec Pharmaceuticals Inc. lost $9.7M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Fennec Pharmaceuticals Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $21.1M | $23.8M | $13.3M | $26.6M | $36.8M |
| Debt incl. finance leases | $5.0M | $24.9M | $30.9M | $19.3M | β |
| Debt / equity | 0.3x | β | β | β | β |
| Interest coverage | β | β | β3.8x | 0.6x | β3.0x |
| Current ratio | 13.5x | 5.8x | 3.6x | 6.4x | 6.4x |
| Quick ratio | 13.5x | 5.8x | 3.6x | 6.4x | 6.4x |
| Total assets | $22.4M | $26.9M | $26.9M | $44.9M | $70.6M |
| Total liabilities | $6.6M | $29.5M | $38.5M | $50.8M | $35.1M |
| Shareholders' equity | $15.8M | β$2.6M | β$11.6M | β$5.9M | $35.5M |
| Net debt (β = net cash) | β$16.1M | $1.1M | $17.7M | β$7.3M | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Fennec Pharmaceuticals Inc. passes 0 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 6 | 1 / 7 | 1 / 7 | 5 / 7 | β / 6 | 1 / 7 | 2 / 9 | 6 / 8 | 0 / 7 |
| Accruals ratio | β16.7% | β21.0% | β8.0% | β20.0% | β11.0% | β11.6% | β22.9% | 4.1% | β76.4% | 4.7% |
| Altman Z'' | β | 7.69 | β1.93 | β28.50 | β1.57 | β22.71 | β24.93 | β25.40 | β10.24 | β4.88 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.2M | β | $1.5M | $21.3M | $47.5M | $44.6M |
| Net interest income | β | β | β | β | β | β | $0.2M | $0.4M | β | β |
| Gross profit | β | β | β | β | β | β | $1.4M | $20.0M | β | β |
| Research and development | $0.5M | $1.9M | $5.0M | $5.6M | $5.1M | $5.0M | $3.5M | $0.1M | $0.3M | $0.3M |
| Operating income | β$2.9M | β$7.0M | β$10.4M | β$13.0M | β$17.9M | β$17.2M | β$22.6M | β$12.8M | $2.6M | β$6.3M |
| Interest expense | β | β | β | β | β | β | β | $3.4M | $4.1M | $2.1M |
| Pretax income | β$2.8M | β$7.0M | β$7.7M | β$9.0M | β$8.8M | β$9.1M | β$10.5M | β$16.0M | β$0.1M | β$9.6M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | β | $0.4M | $0.1M |
| Net income | β$2.8M | β$7.0M | β$9.9M | β$12.8M | β$18.1M | β$17.3M | β$23.7M | β$16.0M | β$0.4M | β$9.7M |
| Diluted EPS | β$0.22 | β$0.47 | β$0.52 | β$0.64 | β$0.76 | β$0.67 | β$0.90 | β$0.60 | β$0.02 | β$0.34 |
| Diluted shares | 0.01B | 0.02B | 0.02B | 0.02B | 0.00B | 0.03B | 0.03B | 0.03B | 0.03B | 0.03B |
| Cash flow | ||||||||||
| Cash from operations | β$2.1M | β$3.6M | β$7.8M | β$9.1M | β$15.6M | β$14.2M | β$18.1M | β$17.1M | $27.0M | β$12.5M |
| Stock-based compensation | $0.6M | $1.5M | $1.8M | $2.7M | $2.8M | $3.7M | $4.1M | $5.4M | $5.1M | $7.0M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $3.9M | $28.3M | $22.8M | $13.7M | $30.3M | $21.1M | $23.8M | $13.3M | $26.6M | $36.8M |
| Total debt | β | β | β | β | β | $5.0M | $24.9M | $30.9M | $19.3M | β |
| Current assets | β | $28.4M | $23.0M | $13.9M | $31.4M | $22.4M | $26.7M | $26.9M | $44.1M | $67.0M |
| Current liabilities | $0.4M | $1.6M | $1.6M | $2.3M | $2.3M | $1.7M | $4.6M | $7.6M | $6.9M | $10.5M |
| Total assets | $4.0M | $28.4M | $23.0M | $14.1M | $31.4M | $22.4M | $26.9M | $26.9M | $44.9M | $70.6M |
| Total liabilities | $0.4M | $1.6M | $1.6M | $2.3M | $2.3M | $6.6M | $29.5M | $38.5M | $50.8M | $35.1M |
| Shareholders' equity | $3.6M | $26.8M | $21.3M | $11.9M | $29.1M | $15.8M | β$2.6M | β$11.6M | β$5.9M | $35.5M |
| Margins | ||||||||||
| Gross margin | β | β | β | β | β | β | 94.4% | 94.1% | β | β |
| Operating margin | β | β | β | β | β8,942.5% | β | β1,471.6% | β60.1% | 5.4% | β14.1% |
| Net margin | β | β | β | β | β9,054.5% | β | β1,544.9% | β75.5% | β0.9% | β21.8% |
| Net interest share of revenue | β | β | β | β | β | β | 12.7% | 2.1% | β | β |
| Returns | ||||||||||
| Return on capital | β | β | β | β | β | β | β | β167.0% | β | β |
| Return on capital employed | β80.4% | β26.0% | β48.8% | β109.5% | β61.5% | β83.0% | β101.2% | β66.1% | 6.8% | β10.5% |
| Return on equity | β78.1% | β46.5% | β41.1% | β77.0% | β88.5% | β77.4% | β359.2% | β | β | β65.8% |
| Return on assets | β70.2% | β43.5% | β38.5% | β68.9% | β79.5% | β64.4% | β96.1% | β59.6% | β1.2% | β16.9% |
| Return on tangible equity | β78.1% | β26.3% | β46.4% | β107.6% | β62.3% | β110.0% | β | β | β | β27.5% |
| Growth | ||||||||||
| Revenue growth | β | β | β | β | β | β | β | 1,284.5% | 123.7% | β6.1% |
| Share count change | β | 17.6% | 26.2% | 5.0% | β99.9% | 109,630.0% | 1.0% | 1.1% | 2.7% | 4.7% |
| Financial health | ||||||||||
| Debt / equity | β | β | β | β | β | 0.3x | β | β | β | β |
| Interest coverage | β | β | β | β | β | β | β | β3.8x | 0.6x | β3.0x |
| Current ratio | β | 17.3x | 14.0x | 6.1x | 13.4x | 13.5x | 5.8x | 3.6x | 6.4x | 6.4x |
| Quick ratio | β | 17.3x | 14.0x | 6.1x | 13.4x | 13.5x | 5.8x | 3.6x | 6.4x | 6.4x |
| Capital allocation | ||||||||||
| Stock comp / revenue | β | β | β | β | 1,395.5% | β | 266.3% | 25.2% | 10.6% | 15.8% |
| Quality scores | ||||||||||
| Piotroski F-score | β | β | 1.0 | 1.0 | 5.0 | β | 1.0 | 2.0 | 6.0 | 0.0 |
| Altman Z'' | β | 7.7 | β1.9 | β28.5 | β1.6 | β22.7 | β24.9 | β25.4 | β10.2 | β4.9 |
| Accruals ratio | β16.7% | β21.0% | β8.0% | β20.0% | β11.0% | β11.6% | β22.9% | 4.1% | β76.4% | 4.7% |
Source: SEC EDGAR XBRL filings (CIK 0001211583). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
